Friday wrap-up. I sense other medical clinicians and researchers here in addition to market gurus, bench scientists, biostatisticians, and other business specialists, all great at literary expression. We are here because PPHM platform is so reasonable in application, elegant in conception, and imminently sensible in a clinical setting. As a practicing physician who deals with head and neck cancers, I would definitely take either drug, Cotara or Bavituximan, and prescribe both. PPHM's radioactive iodine MAB shuttle rocket, Cotara is a logical approach to solid cancer, where it attacks necrotic core cancer cells, as is the entirely new and different anti-PS platform, PPHM's Bavituximab, a MAB that docks on an exclusive cellular surface site. PPHM has a virtual monopoly on anti-PS by virtue of the company's extensive safety and efficacy trials. The anti-PS antibody Bavituximab attaches to diseased cells, stimulates the body's scavenger immune cells (monocytes)to enter the disease area, and the MAB knocks out cancer blood vessels by attacking feeder artery endothelial cells. And this is the beginning. Fully humanized varieties are on the horizon. Bavituximab is almost certainly more effective when used in combination with irradiation therapy than with chemotherapy. Probably an unbelievable amount of improvement in radiation responses with Bavi. Best for PPHM, the company has its own in-house FDA-approved MAB manufacturing facility, Avid, with high output capacity. In the past two weeks PPHM company officers have been unusually sanguine in their appraisal of emerging survival data, one respected former-Genentec key scientist described it as the most compelling phase II data he has seen. However, exact numbers from PPHM cancer trials are still pending, and an investment today remains speculative. It is my opinion that PPHM professional managers, scientists, and board members of have to date comported themselves with the utmost integrity, and have never overplayed future possibilities. The board and management have made mistakes, and necessity has forced so moves up blind-alleys, but PPHM properties are "the real deal", and in my opinion will be applicable for treating enormous numbers of patients for many years. The price explodes when the money players are all lined up...especially if we stockholders continue to understand the value of the PPHM pipeline.
